PDMR Notification RSU Vesting

PureTech Health PLC

27 July 2023

 

27 July 2023

PureTech Health plc

PDMR Notifications

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases, announces that awards of restricted share units ("RSUs") granted by PureTech on 20 July 2020 to certain directors and other persons discharging managerial responsibilities ("PDMRs") pursuant to its Performance Share Plan ("PSP")  vested on 2 February 2023 following satisfaction of performance conditions measured over the three year period to 31 December 2022.

Each PDMR received vested ordinary shares (after deduction of shares for payroll taxes) on 25 July 2023. The market price per ordinary share in the Company used to calculate the amount payable to the PDMRs and the amount of shares to be issued to PDMRs was 227 pence, being the average closing price of the Company's shares over the three-trading day period immediately preceding the settlement, and the exchange rate used to calculate the cash payment and amount of share settlement was £1: $1.28.

The Company's total issued ordinary share capital is 289,468,159 shares after the share issuance to the PDMRs, 13,264,823 shares of which are held in treasury by the Company.

PDMR Notification

The information contained in the below notification is disclosed in accordance with Article 19 of the EU Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Daphne Zohar Bharatt Chowrira Eric Elenko
2	Reason for the notification
a)	Position/status	Daphne Zohar - Chief Executive Officer Bharatt Chowrira - President and Chief Business, Financial and Operating Officer Eric Elenko - Chief Innovation and Strategy Officer
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	PureTech Health plc
b)	LEI	213800LVPDNO2Z9T9I39
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of PureTech Health plc ISIN GB00BY2Z0H74
b)	Nature of the transaction	Issuance of ordinary shares in net settlement of certain vested RSUs under the PureTech Health Performance Share Plan, after retentions in respect of payroll taxes.
c)	Price(s) and volume(s)	Recipient Price Amount Daphne Zohar 0.01 GBP 65,358 ordinary shares Bharatt Chowrira 0.01 GBP 24,925 ordinary shares Eric Elenko 0.01 GBP 22,709 ordinary shares
d)	Aggregated information - Aggregated volume - Price	Price Aggregate Volume 0.01 GBP 112,992 ordinary shares
e)	Date of the transaction	25 July 2023
f)	Place of the transaction	London Stock Exchange (XLON)

About PureTech Health 

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both US FDA clearance and European marketing authorization and a third (KarXT) that is expected to be filed soon for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Contact:

PureTech

Investor Relations

[e-mail]

 

END